IDiyas

For the Inventor, By the Inventor

Madison, WI, United States of America

Agnieszka Glebocka

LinkedIn
USPTO Granted Patents = 16 


 

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 26(Granted Patents)


Location History:

  • Warsaw, PL (2007 - 2011)
  • Madison, WI (US) (2009 - 2021)

Company Filing History:

goldMedal11 out of 4,119 
 
Wisconsin Alumni Research Foundation
 patents
silverMedal5 out of 95 
 
Arrowhead Pharmaceuticals, Inc.
 patents

Years Active: 2007-2025

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12442002 - RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use (2025-10-14),
2. 12173086 - Alpha-v beta-6 integrin ligands and uses thereof (2024-12-24),
3. 11180529 - Alpha-v beta-6 integrin ligands and uses thereof (2021-11-23),
4. 11174481 - Targeting ligands (2021-11-16),
5. 10294474 - Targeting ligands (2019-05-21),
6. 8785422 - A-ring modified 19-nor-vitamin D analogs and their uses (2014-07-22),
7. 8519169 - Crystallization a 1alpha-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 (2013-08-27),
8. 8217023 - 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring (2012-07-10),
9. 8058265 - 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof (2011-11-15),
10. 7943601 - 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs (2011-05-17),
11. 7879829 - 19-nor-vitamin D analogs with 1,2-dihydrofuran ring (2011-02-01),
12. 7763598 - 1α-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain (2010-07-27),
13. 7648974 - 19-nor-vitamin D analogs with 3,2-dihydrofuran ring (2010-01-19),
14. 7538098 - 19-nor-vitamin D analogs with 1,2 or 3,2 heterocyclic ring (2009-05-26),
15. 7531527 - 2-Propylidene-19-nor-vitamin D compounds (2009-05-12),

Title: Agnieszka Glebocka: Innovator in RNAi Therapeutics

Introduction

Agnieszka Glebocka is a prominent inventor based in Madison, Wisconsin, known for her significant contributions to the field of RNA interference (RNAi) therapeutics. With a total of 16 patents to her name, she has made remarkable strides in developing innovative solutions for various health conditions.

Latest Patents

Among her latest patents, Glebocka has developed RNAi agents for inhibiting the expression of activin receptor-like kinase 7 (ALK7). These agents, along with their compositions and methods of use, provide a novel approach to inhibit the ALK7 gene. The ALK7 RNAi agents and conjugates disclosed in her patents are designed to reduce ALK7 activity, offering potential therapeutic benefits for conditions such as obesity, diabetes, and insulin resistance. Additionally, she has worked on integrin ligands that exhibit serum stability and affinity for αvβ6 integrins, further expanding her impact in the field.

Career Highlights

Glebocka has held key positions at notable organizations, including the Wisconsin Alumni Research Foundation and Arrowhead Pharmaceuticals, Inc. Her work has been instrumental in advancing the understanding and application of RNAi technologies in therapeutic settings.

Collaborations

Throughout her career, Glebocka has collaborated with esteemed colleagues, including Hector Floyd Deluca and Lori A. Plum. These partnerships have contributed to her innovative research and development efforts.

Conclusion

Agnieszka Glebocka's work exemplifies the intersection of innovation and healthcare, particularly in the realm of RNAi therapeutics. Her contributions continue to pave the way for advancements in treating complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…